Featured Education

Pacing the Continuum of Follicular Lymphoma: Integrating Prognostic Tools and Novel Treatment Approaches

Click here to learn more

Transforming Relapsed/Refractory MCL: Exploring New Options for Your Patients

Click here to learn more

Patient Perspectives for PCPs - Tackling the Treatment Paradigms of Obesity, T2D, and Other Metabolic Disorders

Click here to learn more

New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease

Click here to learn more

Expanding Therapy Options for the Treatment of Relapsed or Refractory Multiple Myeloma: BCMA-Directed Therapies

Click here to learn more

Build Your Own Case Study | Obesity: Treating the Whole Patient

Click here to learn more

On Demand Activities

More results...

Therapeutics Areas
Learner Specialties
Expires After
  • On-Demand
The Evolution of HCT, Part 1: Basics and Outcomes
  • Credit: 1.50hr(s)
  • CME, NCPD
  • February 22, 2023 — 
  • February 21, 2024
  • Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
  • Specialties: Bone Marrow Transplantation, Hematology, Oncology
  • Location: Internet Activity Enduring
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 1 in a 5-part series, including the series introduction, basics of HCT, and major advances in HCT outcomes over time.
Enroll Today
View Course
  • On-Demand
CLL-SLL/MTT Episode 2 of 3 - Moving Towards Fixed-Duration Therapy in CLL and SLL
  • Credit: 0.30hr(s)
  • AAPA, CME, CPE, NCPD
  • December 1, 2022 — 
  • December 14, 2023
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: Chronic Lymphocytic Leukemia (CLL), Small lymphocytic lymphoma (SLL)
  • Location: Internet Activity Enduring
The emergence of fixed-duration therapy, which combines two or more drugs within a set timeframe, has shown promise for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, it leads to many clinical questions regarding establishing an optimal combinational therapy and sequence to best fit the needs of the patient. Join us for the second episode of the 3-part educational series First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement as our experts and special guests discuss the implications of the new data in fixed-duration therapy, as well as strategies to promote inclusive clinical trial participation.
Enroll Today
View Course
  • On-Demand
Making the Right Call: Biomarker Testing and Targeting in NSCLC: Part I: Equitable, Guideline-based Testing for Prognosis and Treatment
  • Credit: 0.30hr(s)
  • AAPA, CME, CPE, NCPD
  • November 29, 2022 — 
  • November 28, 2023
  • Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
  • Specialties: Biomarkers, NSCLC
  • Location: Internet Activity Enduring
In the past decade, advances in non-small cell lung cancer (NSCLC) have rapidly evolved with the discovery of targetable mutations and subsequent therapies. However, suboptimal biomarker testing practices and varying adherence to testing guidelines presents a challenge to implementing targeted treatment. Are you ready to test your skills against those of your colleagues? Join us for Part 1 of this question and answer based educational activity Equitable, Guideline-based Testing for Prognosis and Treatment where our oncology experts will: Review guideline recommendations for biomarker testing and treatment selection Present clinical evidence for the use of current and emerging targeted therapies Discuss health disparities in biomarker testing
Enroll Today
View Course
  • On-Demand
New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease
  • Credit: 1.00hr(s)
  • AAPA, CME, CPE, IPCE, NCPD
  • May 31, 2023 — 
  • May 30, 2024
  • Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
  • Specialties: CAR T-Cell Therapy, Multiple Myeloma
  • Location: Internet Activity Enduring
Despite remarkable progress, significant gaps remain in meeting the needs of patients facing relapse in multiple myeloma, particularly among patients with early relapse or triple-class exposed disease. Join us for a groundbreaking Special Edition Med Table Talk episode where we delve into the latest advancements in the treatment of relapsed multiple myeloma (RRMM).  This candid conversation between esteemed faculty experts discusses the latest clinical evidence and rationale for CAR T-cell therapy in early versus late relapse settings and embraces a future pathway where highly effective treatments may be delivered earlier to support increasingly durable responses for complex patient populations.
Enroll Today
View Course
  • On-Demand
The Evolution of HCT, Part 3: Donor Availability
  • Credit: 0.75hr(s)
  • CME, NCPD
  • February 22, 2023 — 
  • February 21, 2024
  • Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
  • Specialties: Bone Marrow Transplantation, Hematology, Oncology
  • Location: Internet Activity Enduring
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 3 in a 5-part series, covering advances in donor availability that have led to expanded access to HCT over time.
Enroll Today
View Course
  • On-Demand
Expanding Therapy Options for the Treatment of Relapsed or Refractory Multiple Myeloma: BCMA-Directed Therapies
  • Credit: 2.00hr(s)
  • CME, EBAH, ECMEC
  • April 13, 2023 — 
  • February 8, 2024
  • Therapeutic Areas: Hematology, Oncology
  • Specialties: Multiple Myeloma
  • Location: Internet Activity Enduring
Join us in this 3-part educational Med Table Talk® on Expanding Therapy Options for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM): BCMA-Directed Therapies as our experts from the US and Western Europe have a candid conversation about the role of BCMA in MM, the clinical implications of new and emerging BCMA-directed therapies, and practical strategies for treatment sequencing.
Enroll Today
View Course
View All MLI Activities
Facebook Twitter Linkedin Instagram
Subscribe to Mailing List
Scroll to Top